Adamantinomatous craniopharyngioma (ACP)
Conditions
Interventions
NTZ and tolizumab combination therapy:NTZ 500 mg orally, tolizumab 12 mg/kg intravenously
NTZ:NTZ 500 mg orally
Sponsors
FuJIan SanBo FuNeng Brain Hospital
Eligibility
Sex/Gender
All
Age
3 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1.Twenty patients with recurrent or surgical residual ACP were recruited (criteria for evaluating the efficacy of solid tumours RECIST 1.1 evaluated on the basis of CT or MRI, with the longest diameter of the lesion being at least 10 mm); 2.Both men and women. 3.Age 3-60. 4.Sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1.Accompanied by hydrocephalus; 2.Impaired consciousness exists; 3.SF-36 scale quantitative quality of life assessment parameters <50 points. 4.Unwillingness to comply with all procedures associated with the study, or failure to comply with protocol requirements, refusal to follow up or cooperate with examinations during the course of the study, entitles the party responsible for the study to suspend the subject without liability. 5.Those who are pregnant or plan to become pregnant within 1 year, breastfeeding women. 6.Those who were unable to cooperate with follow-up visits and did not have family members/carers who were able to attend and support all study visits during the consent process.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Imaging indicators; | — |
Countries
China
Contacts
Public ContactZhixiong Lin
FuJIan SanBo FuNeng Brain Hospital
Outcome results
None listed